Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 4/20 | 0.39 |
| ▸ | MAPT | P10636 | 3/20 | 0.39 |
| ▸ | MEN1 | O00255 | 3/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | SQSTM1 | Q13501 | 1/20 | 0.38 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.38 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13224743 | 0.81 | FFAR4 (0.50) | ALDH1A1PKMLMNAMAPTMEN1 | |
| SCHEMBL1104970 | 0.77 | LMNA (0.35) | ALDH1A1PKMSMN1; SMN2LMNAMAPT | |
| SCHEMBL1104955 | 0.73 | SMN1; SMN2 (0.59) | ALDH1A1PKMSMN1; SMN2LMNAMAPT | |
| SCHEMBL1104965 | 0.71 | POLB (0.69) | ALDH1A1SMN1; SMN2LMNAMAPTMEN1 | |
| SCHEMBL1104957 | 0.70 | ALDH1A1 (0.39) | ALDH1A1PKMSMN1; SMN2LMNAKMT2A | |
| SCHEMBL1104964 | 0.67 | CA2 (0.59) | ALDH1A1SMN1; SMN2HTT | |
| SCHEMBL1104972 | 0.65 | LMNA (0.59) | ALDH1A1SMN1; SMN2LMNAMAPTHTT | |
| SCHEMBL1104961 | 0.62 | PKM (0.35) | ALDH1A1PKMSMN1; SMN2LMNAMEN1 | |
| SCHEMBL1104952 | 0.62 | ALDH1A1 (0.32) | ALDH1A1PKMSMN1; SMN2LMNAMEN1 | |
| SCHEMBL9923630 | 0.61 | CA1 (0.49) | MAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8907101-B2 | Sulfonamide derivatives | PFIZER LIMITED (GB) | 2014-12-09 | — | — | US | disclosed |
| US-8541588-B2 | Sulfonamide derivatives | PFIZER LIMITED (GB) | 2013-09-24 | — | — | US | disclosed |
| US-20120149679-A1 | Sulfonamide Derivatives | ICAGEN, INC. | 2012-06-14 | — | — | US | disclosed |
| US-8153814-B2 | Sulfonamide derivatives | PFIZER LIMITED (GB) | 2012-04-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149679-A1 | Sulfonamide Derivatives | SULT2A1, SULT1A1, TPST2 | ALDH1A1 1369/4885PKM 367/4885SMN1; SMN2 86/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.